Tomas G Olsson (Former)
1 – 20 of 56
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer
(
- Contribution to journal › Article
-
Mark
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease : A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
(
- Contribution to journal › Article
- 2020
-
Mark
In Vivo Veritas : 18F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 Inhibitors
(
- Contribution to journal › Article
- 2019
-
Mark
Synthesis, Radiolabeling, and in Vitro and in Vivo Evaluation of [
18
F]ENL30 : A Potential PET Radiotracer for the 5-HT
7
Receptor
(
- Contribution to journal › Article
-
Mark
Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease
(
- Contribution to journal › Article
- 2017
-
Mark
Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology
(
- Contribution to journal › Article
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article
- 2015
-
Mark
Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
-
Mark
Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
- 2014
-
Mark
(18)F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.
(
- Contribution to journal › Article
-
Mark
Change in Cell Death Markers During (177)Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma.
(
- Contribution to journal › Article
-
Mark
Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
- 2013
-
Mark
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
A niobium water target for routine production of [(18)F]Fluoride with a MC 17 cyclotron.
(
- Contribution to journal › Article
- 2012
-
Mark
Repeated Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Targeting Free Prostate-Specific Antigen for In Vivo Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone.
(
- Contribution to journal › Article
-
Mark
Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody.
(
- Contribution to journal › Article
-
Mark
Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
(
- Contribution to journal › Article